Related Experiment Video
Updated: Jun 2, 2026

Microfluidics in Assessing Platelet Function
Published on: November 8, 2024
Coagulation status in patients with coronary artery disease taking 100 mg aspirin and healthy volunteers using
1Institute of Experimental and Clinical Pharmacology and Toxicology, Medical Faculty Mannheim, University of Heidelberg, Heidelberg, Germany.
Insights
Age increases blood clot risk. Elderly individuals and those with coronary artery disease show higher coagulability compared to young adults, as measured by rotation thrombelastography (ROTEM®).
Area of Science:
- Hematology
- Gerontology
- Cardiovascular Medicine
Background:
- Age is a significant risk factor for thromboembolic events.
- Previous studies indicated increased procoagulant activity in elderly patients with coronary artery disease using thrombelastography.
- Understanding age-related coagulation differences is crucial for cardiovascular health.
Purpose of the Study:
- To investigate age-related differences in coagulation status.
- To compare coagulation parameters in patients with coronary artery disease, healthy elderly, and healthy young volunteers.
- To utilize rotation thrombelastography (ROTEM®) and PFA-100® for detailed analysis.
Main Methods:
- Employed rotation thrombelastography (ROTEM®) and PFA-100® assays.
- Assessed clot formation time (CFT) and maximum clot formation (MCF) using ROTEM® (EXTEM).
- Evaluated closure times using the collagen/epinephrine cartridge of the PFA-100®.
Main Results:
- Healthy young volunteers exhibited significantly longer clot formation times (CFT) and lower maximum clot formation (MCF) compared to healthy elderly and coronary artery disease patients.
- No significant difference in CFT or MCF was observed between healthy elderly individuals and patients with coronary artery disease.
- PFA-100® showed a trend towards longer closure times in young volunteers, but differences were not statistically significant.
Conclusions:
- Findings indicate age-related variations in thrombelastographic parameters.
- ROTEM® analysis suggests increased blood coagulability in both healthy elderly individuals and patients with coronary artery disease compared to younger adults.
- These results highlight the impact of aging and cardiovascular disease on hemostasis.
Abstract:
Previous investigation revealed that age is a major risk factor for thomboembolic events. Earlier studies with thrombelastography have demonstrated procoagulant activity in elderly patients with coronary artery disease. The aim of the present study was to investigate age-related differences in the coagulation status of patients with documented coronary artery disease, healthy elderly and healthy young volunteers with the rotation thrombelastography (ROTEM®) and PFA-100®. Measured with ROTEM®, mean clot formation time (CFT (EXTEM)) in healthy young volunteers (120.8 ± 73.5 s) was significantly longer than in healthy elderly (78.3 ± 36.7 s, p < 0.05) and in patients with coronary artery disease (74.3 ± 59.1 s, p < 0.05). No difference was found between healthy elderly and patients with coronary artery disease. The lowest value for mean maximum clot formation (MCF (EXTEM)) was seen in healthy young volunteers (57.0 ± 6.1 mm) which was significantly different to healthy elderly (61.9 ± 4.8 mm, p < 0.05) and patients with coronary artery disease (65.3 ± 8.4 mm, p < 0.05). No difference could be found between healthy elderly and patients with coronary artery disease, although a trend to higher mean MCF (EXTEM) and lower mean CFT (EXTEM)in patients with coronary artery disease was found. Measured with the collagen/epinephrine cartridge of the PFA-100®, healthy young volunteers (166.4 ± 59.5 s) had numerical but insignificantly longer mean closure times compared to healthy elderly (138.5 ± 53.3 s). These findings point to agerelated differences in thrombelastographic parameters. The ROTEM® analysis indicates an increased coagulability in patients with coronary artery disease and healthy elderly compared to healthy young volunteers.
Related Concept Videos
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Coronary Artery Disease V: Interprofessional Care
Anticoagulant Drugs: Low-Molecular-Weight Heparins
